Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

The neurosurgeon at Northwestern Medicine discussed diagnostic approaches, evolving treatment strategies, and the importance of timely referral in managing peripheral nerve injuries. [WATCH TIME: 3 minutes]

Emerging Considerations in Peripheral Nerve Injury and Surgical Intervention: Kevin Swong, MD

Articles

The trial of the H₃ inverse agonist aims to evalute its ability to reduce cataplexy and improve symptoms in patients with narcolepsy type 1.

Phase 2 Study to Test Therapeutic Potential of Samelisant for Narcolepsy Type 1

New 5-year findings from the National RLS Opioid Registry presented at SLEEP 2025 highlight the long-term stability and dose trends of low-dose opioid therapy in patients with restless legs syndrome.

National RLS Registry Provides Long-Term Insights Into Opioid Use for Restless Legs Syndrome

Members from Nuvig Therapeutics discussed how NVG-2089 could improve the CIDP treatment landscape by offering IVIG-like efficacy with a better safety and administration profile. [WATCH TIME: 3 minutes]

Rationale Behind NVG-2089 as New Therapy for CIDP: Pamela Conley; Alan Glicklich, MD

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

The neuroscientist and physician at Mount Sinai explored the role of sleep-dependent brain clearance in Alzheimer disease and how emerging research is challenging longstanding assumptions.

NeuroVoices: Andrew Varga, MD, on Debating Whether Brain Cleansing Prevents Alzheimer Disease

Senior Director, Patient Management, Care and Rehabilitation Research, National MS Society

The associate vice president of research at the National MS Society discussed a growing research initiative focused on defining and promoting evidence-based psychosocial wellness strategies for individuals with MS. [WATCH TIME: 6 minutes]

Expanding the Scope of Wellness Research in Multiple Sclerosis: Kathy Zackowski, PhD, OTR

Founder and Executive Director, Sumaira Foundation

The executive director of The Sumaira Foundation discussed a newly funded international trial assessing both approved and off-label NMOSD therapies to better inform treatment decisions and patient care. [WATCH TIME: 2 minutes]

Investigating Treatment Differences of Off-Label and Marketed Therapies for NMOSD: Sumaira Ahmed

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

CMSC 2025

PNS 2025

SLEEP 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Expert Insights on Novel NMOSD Treatments

Treatment Options to Manage and Prevent Relapses in NMOSD

Video content above is prompted by the following:

What treatment options are available for NMOSD (Kümpfel 2024)?

Discuss options available for treatment of the acute phase and relapses and prevention of relapses.

How do the traditional and newer treatments target various aspects of NMOSD pathophysiology?

Three medical experts explore key insights on novel treatments for NMOSD, focusing on relapse management, disability accumulation, and the efficacy of new versus traditional therapies.

This discussion covers the factors leading to relapses and recurring attacks in NMOSD, how disease severity and relapses contribute to disability accumulation, and their impact on patients' quality of life.

Relapses and Disability Accumulation in NMOSD

This discussion examines how disability accumulation may be influenced by the use of less efficacious treatments, compares the efficacy of novel and traditional NMOSD agents in clinical practice, and reviews relapse rates associated with FDA-approved treatments versus off-label and older therapies.

Treatments With Higher Efficacy and Relapses in NMOSD

This discussion examines the 138-week data on ravulizumab for NMOSD, focusing on long-term relapse rates, and share practical tips for effective NMOSD management in clinical settings.

Ravulizumab Long-Term Data and Management of NMOSD

Jacqueline Nicholas, MD, MPH, discusses the evolution of NMOSD pathophysiology understanding and the critical role of the complement system in its development.

The Evolving Understanding of NMOSD Pathophysiology and the Role of Complement System

Jacqueline Nicholas, MD, MPH, discusses available treatment options for NMOSD, including management of acute phases, relapses, and symptom control, as well as how both traditional and newer therapies address different aspects of NMOSD pathophysiology.

Jacqueline Nicholas, MD MPH discusses the importance of targeting NMOSD through different mechanisms of action and highlight key points for communicating with neurologists about the role of the complement system in the disease.

Importance of Diverse Mechanisms of Action to Effectively Treat NMOSD

Sean Pittock, MD, discusses how complement inhibitors are positioned in the treatment landscape of neuromyelitis optica spectrum disorder, providing an overview of ravulizumab, the most recent FDA-approved treatment, including its development rationale, half-life, dosing regimen, and new signals from the recently presented 138-week long-term extension data at EAN 2024.



Complement Inhibitors in NMOSD

Sean Pittock, MD, discusses the risks of meningococcal infection associated with eculizumab and ravulizumab in phase 3 and long-term extension studies, as well as his interpretation of the concerns surrounding meningococcal vaccination and its potential impact on relapse activity.


Meningococcal Infection and NMOSD

Sean Pittock, MD, discusses the long-term efficacy and safety results of other FDA-approved treatments for neuromyelitis optica spectrum disorder, including satralizumab, inebilizumab, and the off-label use of rituximab.

Long-term NMOSD Data

Sean Pittock, MD, discusses how he utilizes long-term data in his clinical practice for treating neuromyelitis optica spectrum disorder and offers advice for physicians on incorporating these insights into patient care.

Use of Long-term NMOSD Data in Clinical Practice

 video series brings together pairs of expert clinicians and physicians to independently provide their insights on the latest and most up-to-date clinical care for specific neurologic diseases and disorders.

Treatment Options to Manage and Prevent Relapses in NMOSD

EP: 1.Relapses and Disability Accumulation in NMOSD

EP: 2.Treatments With Higher Efficacy and Relapses in NMOSD

EP: 3.Ravulizumab Long-Term Data and Management of NMOSD

EP: 4.The Evolving Understanding of NMOSD Pathophysiology and the Role of Complement System

EP: 5.Treatment Options to Manage and Prevent Relapses in NMOSD

EP: 6.Importance of Diverse Mechanisms of Action to Effectively Treat NMOSD

EP: 7.Complement Inhibitors in NMOSD

EP: 8.Meningococcal Infection and NMOSD

EP: 9.Long-term NMOSD Data

EP: 10.Use of Long-term NMOSD Data in Clinical Practice

Newsletter